Postnatal period of caffeine treatment and time of testing modulate the effect of acute caffeine on cortical epileptic afterdischarges in rats.
Recently, we have found that postnatal caffeine treatment results in a dose-dependent pro- or anticonvulsant effect during brain maturation which effect is transient and disappears in adult rats. The aim of the present study was to determine whether the developmental period of chronic caffeine treatment and the age of testing are crucial for the effects of acute caffeine on cortical epileptic afterdischarges (ADs) in rats. Rhythmic electrical stimulation of somatosensory cortex was applied to elicit EEG and motor phenomena in 18- and 25-day-old rats, respectively. Acute injection of caffeine (10 and 20mg/kg s.c.) decreased the threshold for stimulation-bound movements in both age groups while it increased the thresholds for spike-and-wave ADs and clonic seizures accompanying them at P25. Acute caffeine had a similar effect on thresholds for spike-and-wave ADs and clonic seizures in 25-day-old rats exposed to the methylxanthine at P7-P11 and P13-17, respectively. Though caffeine administration per se did not change the duration of ADs at P18 it produced either a pro- or anticonvulsant effect after postnatal treatment (P7-P11 and P13-P17, respectively). However, acute caffeine exerted a prolongation of ADs at P25 which effect was alleviated after both developmental periods of treatment. Taken together, acute caffeine effects on cortical epileptic ADs in rats can be modulated by the postnatal period of treatment and age of testing.
Tchekalarova
Jana
J
Institute of Neurobiology, Acad G Bonchev Str, Bl 23, Bulgarian Academy of Sciences, Sofia 1113, Bulgaria. jane_tch@yahoo.com
Kubová
Hana
H
Mares
Pavel
P
D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000375:Aging / Q000187:drug effects / Q000502:physiology; D000818:Animals; D000831:Animals, Newborn; D000927:Anticonvulsants / Q000494:pharmacology; D002110:Caffeine / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects* / Q000254:growth & development / Q000503:physiopathology*; D003292:Convulsants / Q000494:pharmacology; D004558:Electric Stimulation / Q000009:adverse effects; D004827:Epilepsy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology*; D008297:Male; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology
D000927:Anticonvulsants; D003292:Convulsants; D002110:Caffeine